%0 Journal Article %T Markers of resistance to anti-EGFR therapy in colorectal cancer %A Shaib, Walid %A Mahajan, Reena %A El-Rayes, Bassel %J Journal of Gastrointestinal Oncology %D 2013 %B 2013 %9 %! Markers of resistance to anti-EGFR therapy in colorectal cancer %K %X Epidermal growth factor receptor (EGFR) is a therapeutic target in colorectal cancer (CRC). The benefit from EGFR inhibitors appears to be limited to a subset of patients with CRC. Mechanisms of resistance to EGFR inhibitors are being identified. KRAS codon 12 activating mutation is a predominate mechanism of resistance to EGFR inhibitors in around 40% of patients with advanced CRC. Other potential mechanisms of resistance include ligand expression, increased EGFR number, mutations of BRAF and activation of alternate signaling pathways. %U https://jgo.amegroups.org/article/view/1154 %V 4 %N 3 %P 308-318 %@ 2219-679X